BRCA2

Biomarkers

BRCA2 is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
BRCA2 pathogenic variants	Germline Variant	21	37
BRCA2 oncogenic variants	Somatic Variant	15	27

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA